Invest in smarter healthcare

Lumos Diagnostics is a publicly-traded company listed on the Australian Securities Exchange (ASX:LDX).

Register for Lumos investor news and updates.

By entering your email address you are agreeing to our Privacy Policy.

Lumos Diagnostics Holdings Ltd

Key statistics for LDX

Market price
$0.043
Market cap
$-
Volume
14,820,295
Day low
$0.038
Day high
$0.043
Change
$0.006(16.216%)
03/10/2024 9:10 am Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study 310.2KB (3 pages)
25/09/2024 12:09 pm Lumos Awarded National Contract with MediGroup for FebriDx 284.5KB (2 pages)
23/09/2024 4:09 pm Ceasing to be a substantial holder 65.7KB (1 pages)
23/09/2024 2:09 pm Change in substantial holding from RYD 177.0KB (3 pages)
23/09/2024 9:09 am Investor Roadshow Presentation 14.9MB (55 pages)
20/09/2024 10:09 am Lumos Achieves First Phase 2 Milestone in Hologic Agreement 245.8KB (3 pages)
19/09/2024 4:09 pm Change in substantial holding 161.3KB (2 pages)
16/09/2024 2:09 pm Change in substantial holder 193.7KB (2 pages)
16/09/2024 10:09 am Change in substantial holding 175.1KB (2 pages)
16/09/2024 9:09 am Lumos Appoints Thermo Fisher Scientific as US Distributor 189.2KB (2 pages)
13/09/2024 3:09 pm Change in substantial holding from RYD 181.3KB (3 pages)
12/09/2024 10:09 am Application for quotation of securities - LDX 20.7KB (8 pages)
11/09/2024 9:09 am Letter to Ineligible Shareholders 134.5KB (3 pages)
11/09/2024 9:09 am Letter to Eligible Shareholders 19.2MB (98 pages)
11/09/2024 9:09 am Retail Entitlement Offer Booklet 18.9MB (94 pages)
11/09/2024 9:09 am Retail Entitlement Offer Opens 237.7KB (2 pages)
06/09/2024 8:09 am Lumos Successfully Completes Institutional Entitlement Offer 261.3KB (3 pages)
04/09/2024 2:09 pm Becoming a substantial holder 210.3KB (2 pages)
04/09/2024 12:09 pm Ceasing to be a substantial holder 125.6KB (2 pages)
04/09/2024 10:09 am Proposed issue of securities - LDX 18.5KB (5 pages)
04/09/2024 10:09 am Proposed issue of securities - LDX 24.8KB (7 pages)
04/09/2024 10:09 am Entitlement Offer Cleansing Notice 232.0KB (3 pages)
04/09/2024 10:09 am Investor Presentation 18.1MB (53 pages)
04/09/2024 10:09 am Lumos Announces $10m Equity Raising and Welcomes Tenmile 332.8KB (6 pages)
04/09/2024 9:09 am Trading Halt 631.9KB (2 pages)
03/09/2024 4:09 pm Lumos Announces Intention to Undertake Entitlement Offer 334.9KB (3 pages)
27/08/2024 9:08 am Appendix 4G and Corporate Governance Statement 808.1KB (27 pages)
27/08/2024 9:08 am FY24 Full Year Results Announcement 287.8KB (5 pages)
27/08/2024 9:08 am FY24 Annual Report 3.4MB (77 pages)
27/08/2024 9:08 am FY24 Appendix 4E 201.7KB (2 pages)
26/08/2024 8:08 am Lumos and BDI Progress New Point of Care Test 329.7KB (3 pages)
05/08/2024 10:08 am Lumos Receives Research & Development Tax Rebate 286.5KB (2 pages)
01/08/2024 10:08 am Q4 FY24 Investor Presentation 1.3MB (20 pages)
31/07/2024 8:07 am Quarterly Activities/Appendix 4C Cash Flow Report 612.1KB (12 pages)
29/07/2024 2:07 pm Q4 FY24 Results Investor Briefing Invitation 282.4KB (2 pages)
11/07/2024 8:07 am Notification of cessation of securities - LDX 19.3KB (6 pages)
09/07/2024 8:07 am Lumos Expands Henry Schein FebriDx Distribution Partnership 273.1KB (3 pages)
04/07/2024 8:07 am Lumos Expands Distribution for FebriDx in AUS and NZ 425.6KB (3 pages)
19/06/2024 9:06 am Lumos Receives US$400k Phase 1 Milestone from Hologic 283.0KB (2 pages)
13/06/2024 9:06 am Change of Director's Interest Notice - CR 311.5KB (2 pages)
13/06/2024 9:06 am Change of Director's Interest Notice - SL 317.7KB (2 pages)
04/06/2024 9:06 am Lumos Receives Second US$5 million Hologic IP Payment 245.3KB (3 pages)
28/05/2024 11:05 am March 2024 Appendix 4C - Correction 564.5KB (7 pages)
06/05/2024 8:05 am Lumos Achieves Key Phase 1 Milestone in Hologic Agreement 309.0KB (3 pages)
02/05/2024 2:05 pm Lumos quarterly update video interview with CEO, Doug Ward 221.5KB (2 pages)
01/05/2024 12:05 pm Notification regarding unquoted securities - LDX 21.3KB (8 pages)
23/04/2024 9:04 am Quarterly Activities/Appendix 4C Cash Flow Report 560.2KB (11 pages)
08/04/2024 9:04 am Lumos announces positive FebriDx paediatric study results 374.9KB (4 pages)
02/04/2024 5:04 pm Change in substantial holding 154.1KB (2 pages)
02/04/2024 3:04 pm Application for quotation of securities - LDX 21.1KB (8 pages)
02/04/2024 3:04 pm Section 708A Cleansing Statement 191.8KB (2 pages)
29/02/2024 5:02 pm Change in substantial holding 229.5KB (2 pages)
28/02/2024 8:02 am Half Year Results Investor Presentation 3.8MB (32 pages)
28/02/2024 8:02 am Appendix 4D and Half Year Report 1.4MB (28 pages)
23/02/2024 11:02 am 1H FY24 Results Investor Briefing Invitation 252.9KB (2 pages)
14/02/2024 4:02 pm Change in substantial holding 177.2KB (2 pages)
12/02/2024 9:02 am Lumos Appoints Henry Schein as US Distributor for FebriDx 284.8KB (2 pages)
05/02/2024 9:02 am Lumos Investor Roadshow Presentation 1.5MB (25 pages)
31/01/2024 9:01 am Investor Information Sessions 286.7KB (2 pages)
31/01/2024 9:01 am Quarterly Activities/Appendix 4C Cash Flow Report 599.4KB (12 pages)
19/01/2024 2:01 pm Proposed issue of securities - LDX 30.2KB (6 pages)
19/01/2024 2:01 pm Notification regarding unquoted securities - LDX 34.1KB (9 pages)
17/01/2024 12:01 pm Change in substantial holding 166.3KB (2 pages)
16/01/2024 10:01 am New Hologic Agreements Investor Briefing Presentation 524.2KB (8 pages)
16/01/2024 10:01 am Additional Information Regarding Agreements with Hologic 229.5KB (3 pages)
15/01/2024 2:01 pm Notification of cessation of securities - LDX 27.7KB (6 pages)
15/01/2024 2:01 pm Investor Briefing on new Hologic Agreements 258.3KB (2 pages)
11/01/2024 9:01 am Lumos Signs Major Development and IP Agreements with Hologic 236.3KB (3 pages)
07/12/2023 2:12 pm Change in substantial holding 240.8KB (2 pages)
06/12/2023 8:12 am Commercial Operations Update Webinar Presentation 19.9MB (12 pages)
04/12/2023 1:12 pm Commercial Update Webinar US Product Launch Activities 211.9KB (2 pages)
04/12/2023 8:12 am Lumos Diagnostics FY2023 Full Year Results Webinar 211.0KB (2 pages)
14/11/2023 2:11 pm Becoming a substantial holder from RYD 171.6KB (2 pages)
03/11/2023 3:11 pm Change in substantial holding 216.9KB (2 pages)
03/11/2023 11:11 am Section 708A Cleansing Statement 293.6KB (2 pages)

Details of the Entitlement Offer

On 3 September 2024, The Company announced its intention to undertake a pro rata accelerated non-renounceable entitlement offer (Entitlement Offer), to raise up to approximately A$10.0 million (before costs) at a price of A$0.038 (3.8 cents) per fully paid ordinary share (Share), on the basis of 1 new Share for every 1.82 Shares held as at 7.00pm (Sydney time) on the record date of Friday, 6 September 2024 (Record Date).

The offer price of A$0.038 per Share represents a 17.4% discount to the last closing Share price of $0.046 (as at 3 September 2024) and a 12.0% discount to the 5-day VWAP of $0.0432 (as at 3 September 2024). New Shares issued under the Entitlement Offer will rank equally with the existing Shares on issue.

The Entitlement Offer will provide eligible shareholders with the opportunity to take up new Shares proportional to their shareholding and mitigate the effect of dilution. Eligible shareholders who do not take up their entitlement under the Entitlement Offer in full or in part will not receive any value in respect to those entitlements not taken up.

Use of Funds

Funds raised from the Entitlement Offer are intended to be applied towards: (a) completion of the FebriDx Clinical Laboratory Improvement Amendment (CLIA) waiver trial in the US, product development, sales & marketing activities; (b) general working capital; and (c) costs of the Entitlement Offer.

Completion of the Institutional Entitlement Offer

The Institutional Entitlement Offer to raise approximately A$3.1 million via the issue of approximately 81.7 million new shares was well supported by eligible institutional shareholders as announced on 6 September 2024.

New shares were issued at a fixed price of A$0.038 (3.8 cents) per share and rank equally with existing shares from allotment.

Commencement of Retail Entitlement Offer

The Retail Entitlement Offer to raise approximately A$6.9 million via the issue of approximately 182.8 million new shares is now open and will close at 5.00pm (AEST) on Wednesday, 2 October 2024.

Eligible Retail Shareholders (defined below) who held shares in Lumos as at 7:00pm (AEST) on the Record Date of Friday, 6 September 2024 will be invited to participate in the Retail Entitlement Offer at the same offer price and offer ratio as the participants in the Institutional Entitlement Offer, being $0.038 (3.8 cents) per share and an offer ratio of 1 for 1.82.

Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer should carefully read the Retail Offer Booklet and accompanying personalised entitlement form below.

Offer Timetable

Activity Date
Announcement of the Entitlement Offer Wednesday, 4 September 2024
Institutional Entitlement Offer launch Prior to 12.00pm (AEST) on Wednesday, 4 September 2024
Results of Institutional Entitlement Offer announced and Trading Halt lifted Friday, 6 September 2024
Record Date for eligibility under the Entitlement Offer 7.00pm (AEST) on Friday, 6 September 2024
Retail Offer Booklet lodged with the ASX Wednesday, 11 September 2024
Retail Entitlement Offer opens Wednesday, 11 September 2024
Settlement of New Shares issued under the Institutional Entitlement Offer Wednesday, 11 September 2024
Allotment of New Shares under the Institutional Entitlement Offer Thursday, 12 September 2024
New Shares issued under the Institutional Entitlement Offer commence trading on ASX Friday, 13 September 2024
Last day to extend Retail Entitlement Offer Before 12.00pm (AEST) on 27 September 2024
Closing Date of Retail Entitlement Offer Wednesday, 2 October 2024
Results of Retail Entitlement Offer announced Tuesday, 8 October 2024
Settlement of New Shares issued under the Retail Entitlement Offer Wednesday, 9 October 2024
Allotment of New Shares issued under the Retail Entitlement Offer Before 12.00pm (AEST) on Wednesday, 9 October 2024
New Shares issued under the Retail Entitlement Offer commence trading on ASX Thursday, 10 October 2024

FAQs

  1. Why is Lumos conducting this Entitlement Offer?
    The proceeds from the Entitlement Offer will be allocated towards completing strategic growth initiatives, including the FebriDx CLIA waiver trial in the US, advancing product development, driving sales and marketing activities, providing general working capital, and covering costs associated with the Entitlement Offer itself.
  2. Who is eligible to participate in the Entitlement Offer?

    Shareholders who are eligible to participate in the Entitlement Offer (Eligible Retail Shareholders) are shareholders who:

    • are registered as a holder of Shares in the Company as at 7.00pm (AEST) on the Record Date; and
    • have a registered address on the Company's share register that is in Australia;
    • who are not in the US nor acting for the account or benefit of a person in the US or else outside Australia;
    • do not hold Shares on behalf of another person who reside outside Australia (unless they hold Shares in another eligible capacity); and
    • were not invited to participate in the Institutional Entitlement Offer or treated as an ineligible institutional shareholder for that purpose. Any Retail Shareholders who are not Eligible Retail Shareholders are Ineligible Retail Shareholders.

    The Company reserves the right to determine whether a Shareholder is an Eligible Retail Shareholder or an Ineligible Retail Shareholder.

  3. Who do I contact if I haven't received my paperwork yet
    For further information on the Entitlement Offer, if you have questions on how to complete the Entitlement and Acceptance Form, or have lost your Entitlement and Acceptance Form and would like a replacement form, you may contact the Lumos Diagnostics Company Secretary on +61 3 9087 1598 between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail [email protected].
  4. Who do I contact if I have questions?
    For further information on the Entitlement Offer, if you have questions on how to complete the Entitlement and Acceptance Form, or have lost your Entitlement and Acceptance Form and would like a replacement form, you may contact the Lumos Diagnostics Company Secretary on +61 3 9087 1598 between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail [email protected].

"Lumos represents a compelling investment opportunity. We have secured strategic partnerships with leading healthcare companies. We are expanding our commercial services division across human health, animal health, food testing and molecular testing. We have secured key FDA clearances for our Point-of-care products. Collectively, our Company has firm foundations for considerable revenue growth."

Doug Ward | Lumos CEO and MD